FindTrial
Sign In

Effect of recombinant human erythropoietin combined with iron on anemia treatment in different time points during perioperative period of total hip arthroplasty: a prospective randomized controlled trial

Effect of recombinant human erythropoietin combined with iron on anemia treatment in different time points during perioperative period of total hip arthroplasty: a prospective randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026064
Enrollment
Unknown
Registered
2019-09-20
Start date
2019-09-20
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total hip arthroplasty

Interventions

A:Iron plus rHuEPO 7 days before operation
B:Iron plus rHuEPO 7 days before operation
C:Iron plus rHuEPO 0 days before operation

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged 18-85 years, to undergo total hip arthroplasty, diagnosis of iron deficiency anemia, sign informed consent.

Exclusion criteria

Exclusion criteria: History of drug allergy; Severe hepatic and renal dysfunction.

Design outcomes

Primary

MeasureTime frame
transfusion rate;Hemoglobin;DVT rate;—

Countries

China

Contacts

Public ContactZongke Zhou

West China Hospital, Sichuan University

zhouzongke@scu.edu.cn+86 13514455855

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026